☆
Watchlist
Log in
Sign-up
INVEX Therapeutics Ltd (ixc) Logo

INVEX Therapeutics Ltd (IXC)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

IXC Chart

Snapshot

IXC's Principal Activity is the reformulation of Exenatide to optimise the delivery of the drug for patients with IIH, completing regulatory submissions and feedback from global regulatory bodies including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a Phase III clinical trial in IIH, and the prosecution of the Group's patent portfolio.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -11.45%
vs ASX 200 (1yr) -14.70%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,378 of 2,413
Sector Rank 113 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies THC / PAB / DXB
EPS -$0.04
DPS $0.00
Book Value Per Share $0.43

Broker Consensus

IXC is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Invex Therapeutics Ltd (IXC) is a biopharmaceutical company focused on the repurposing of an approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Subiaco WA 6008
Website www.invextherapeutics.com
Registry Automic Group
Auditor BDO Audit (WA) Pty Ltd
Date Listed 5 Jul 2019

Upcoming Calendar (Forecasted)

Date Event
26/08/2022 Report (Prelim)
26/08/2022 Report (Annual)
21/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Megan Baldwin Non-Executive Director Feb 2021

Dr Megan Baldwin

Non-Executive Director

Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications. Dr Baldwin is CEO and Managing Director of Opthea Limited (ASX: OPT; NASDAQ: OPT). Under Dr Baldwin's leadership, Opthea has advanced its ophthalmology program through Phase I and Phase II clinical development. It was added to the S&P/ASX 300 in June 2020 and in October 2020 completed initial public offering (IPO) and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech.
Dr Thomas (Tom) Duthy Executive Director Oct 2020

Dr Thomas (Tom) Duthy

Executive Director

Dr Duthy has over 15 years of financial markets experience having worked in sell-side equity research, and senior executive roles across investor relations and corporate development. Dr Duthy is the Founder and CEO of Nemean Group Pty Ltd. Prior to establishing Nemean in October 2018, Dr Duthy was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX). Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.

Dr Alexandra J Sinclair Chief Scientific Officer,Executive Director Jun 2019

Dr Alexandra J Sinclair

Chief Scientific Officer,Executive Director

Dr Sinclair is a Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, UK. She runs the Headache service and Idiopathic Intracranial Hypertension Service at University Hospital Foundation Trust. Professor Sinclair is on the MRC Neuroscience and Mental Health Board and the Midland Neuroscience Teaching and Research Fund Board, as well as being Chair of the Brain Research UK Scientific Advisory Board. Previously, she was an elected board member of the IHS and was the Deputy Chair for the Association for British Neurologists grouping for Headache and Pain (ABN AAG). She was on the research committee for the Association for British Neurologists and was also the previous patron of the patient charity IIH UK.

Mrs Narelle Warren Chief Financial Officer,Company Secretary Mar 2019

Mrs Narelle Warren

Chief Financial Officer,Company Secretary

Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.

Mr David McAuliffe Non-Executive Director Mar 2019

Mr David McAuliffe

Non-Executive Director

Mr McAuliffe is an experienced company director and entrepreneur who has had over twenty years' experience, in the international biotechnology field. During that time, he was involved in capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. Mr McAuliffe is the President of the Dyslexia - Speld Foundation WA (Inc).

Dr Jason Loveridge Non-Executive Chairman,Non-Executive Director Mar 2019

Dr Jason Loveridge

Non-Executive Chairman,Non-Executive Director

Dr Loveridge is a founder of Invex and also CEO of 4SC AG, a German publicly listed oncology company. He has more than thirty years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has transactional experience in the sale and partnering of biotechnology assets.

Show All

Director Transactions

IXC directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
08/04/21 Megan Baldwin Issued 400,000 $0.775 $310,000 Issue of options
18/11/20 Thomas (Tom) Duthy Issued 800,000 $0.805 $644,000 Issue of options
22/11/19 Alexandra Sinclair Issued 800,000 $0.71 $568,000 Issue of options
22/11/19 David McAuliffe Issued 200,000 $0.71 $142,000 Issue of options
22/11/19 Jason Loveridge Issued 800,000 $0.71 $568,000 Issue of options
22/11/19 Narelle Warren Issued 400,000 $0.71 $284,000 Issue of options
Show All

Director Interests

The current holdings of IXC directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Alexandra Sinclair 27/08/2021 2,500,000 N/A 800,000 N/A
Thomas (Tom) Duthy 27/08/2021 N/A 106,923 800,000 N/A
Megan Baldwin 27/08/2021 N/A N/A 400,000 N/A
Jason Loveridge 27/08/2021 3,374,246 N/A 800,000 N/A
Narelle Warren 27/08/2021 N/A 200,000 400,000 N/A
David McAuliffe 27/08/2021 N/A 3,350,001 200,000 N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 4, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Tattarang 8,846,154 11.77%
Tisia Nominees Pty Ltd <Henderson Family A/C> 4,000,000 5.32%
Anthony Grist 3,597,700 4.79%
Dr Jason Loveridge 3,374,462 4.49%
Mr David Jerimiah Mcauliffe 3,350,001 4.46%
Jk Nominees Pty Ltd <The Jk A/C> 3,000,000 3.99%
Alexandra Jean Sinclair 2,500,000 3.33%
Mrs Kathryn Salkilld 2,293,000 3.05%
The University Of Birmingham 2,000,000 2.66%
Bannaby Investments Pty Limited <Bannaby Super Fund A/C> 1,625,000 2.16%
Sunset Capital Management Pty Ltd <Sunset Superfund A/C> 1,518,175 2.02%
BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <DRP A/C> 1,390,000 1.85%
Cityscape Asset Pty Ltd <Cityscape Family A/C> 1,250,000 1.66%
Citicorp Nominees Pty Limited 1,184,837 1.58%
Sandhurst Trustees Ltd <Collins St Value Fund A/C> 1,081,924 1.44%
J P Morgan Nominees Australia Pty Limited 655,050 0.87%
Peter Kyros Pty Ltd <Kyros Sf A/C> 583,616 0.78%
Palla Nominees Pty Ltd <P C Blackman S/F No 2 A/C> 580,000 0.77%
HSBC Custody Nominees (Australia) Limited 561,504 0.75%
Magaurite Pty Ltd <Peter Nelson Super Fund A/C> 560,000 0.75%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 235 517 254 439 92 1,537

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Tattarang Pty Ltd 04/08/2021 8,846,154 11.77
Tisia Nominees Pty Ltd 04/08/2021 4,000,000 5.32

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.60 30 June
2020 $1.30 30 June
IXC Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.